Nature Study: No Evidence of Embryonic Stem Cell
Advantage in Treating Diabetes
Media reports that a study published this week in Nature provides new
evidence that embryonic stem cells (ESCs) provide the best avenue for
treating diabetes are wildly off the mark. The study shows no such
thing:
- The study was not about embryonic stem cells, and did nothing to show
their superiority over adult stem cells or their usefulness for
diabetes.
- The study did confirm that adult beta cells (which produce insulin)
can regenerate in adults, without adding any foreign cells from embryos
or anywhere else. While the authors did not find evidence that adult
pancreatic stem cells (which would be capable of producing beta cells)
exist, they also found that adult beta cells themselves are capable of
regenerating. The study provides support for a particular theory as to
how these adult cells regenerate - and it offers a new avenue for
research and possible therapies that would not have to use ESCs. Another
such avenue was recently announced by researchers at Massachusetts
General Hospital, who cured diabetic mice by injecting them with donor
spleen cells - it seems these cells "retrained" the mice's immune
systems to stop attacking their own insulin-producing cells, allowing
new cells to regenerate (possibly from their own remaining beta cells)
without adding new stem cells from any outside source. The Boston Globe
called this "a surprising breakthrough that could soon be tested in
local patients and open a new chapter in diabetes research." (S. Kodama
et al., in Science 302, 1223-1227; 14 Nov 2003; Boston Globe, Nov. 14,
2003, p. A2).
- Recent studies strongly call into question the capability of
embryonic stem cells for treating juvenile diabetes.
Researchers at the University of Calgary, for example, have found
that the insulin-producing cells derived from ESCs are not the "beta
cells" needed to reverse diabetes. While the cells produced some
insulin, they failed to function as a normal beta cell and to produce
the insulin when it was needed; when placed in mice they did not reverse
diabetes but only formed teratomas (tumors) (S. Sipione et al.,
"Insulin expressing cells from differentiated embryonic stem cells
are not beta cells," Diabetologia 47, 499-508, March 2004; published online 14
February 2004). And an author of the new Nature study also co-authored a
recent study acknowledging that human embryonic stem cells spontaneously
develop genetic "abnormalities" in culture -- a problem that may prevent
any clinical use of these cells in humans for a long time to come (C.
Cowan, D. Melton et al., in The New England Journal of Medicine 350,
1353-1356, March 25, 2004, published online March 3, 2004).
New advances in adult cell therapies provide scientifically
well-grounded reasons for hope in their own right. They should not be
twisted into yet another political weapon by those fixated on embryonic
stem cell research.